Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.06
PMC's Cash to Debt is ranked lower than
53% of the 496 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.70 vs. PMC: 0.06 )
PMC' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.06

Equity to Asset 0.54
PMC's Equity to Asset is ranked higher than
82% of the 496 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.44 vs. PMC: 0.54 )
PMC' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.84
Current: 0.54

0.44
0.84
F-Score: 5
Z-Score: 3.93
M-Score: -3.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 3.17
PMC's Operating margin (%) is ranked higher than
71% of the 472 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. PMC: 3.17 )
PMC' s 10-Year Operating margin (%) Range
Min: -2.49   Max: 6.57
Current: 3.17

-2.49
6.57
Net-margin (%) 1.08
PMC's Net-margin (%) is ranked higher than
63% of the 472 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.34 vs. PMC: 1.08 )
PMC' s 10-Year Net-margin (%) Range
Min: -1.98   Max: 4.02
Current: 1.08

-1.98
4.02
ROE (%) 4.09
PMC's ROE (%) is ranked higher than
59% of the 464 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.64 vs. PMC: 4.09 )
PMC' s 10-Year ROE (%) Range
Min: -7.79   Max: 27.19
Current: 4.09

-7.79
27.19
ROA (%) 2.10
PMC's ROA (%) is ranked higher than
63% of the 472 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.41 vs. PMC: 2.10 )
PMC' s 10-Year ROA (%) Range
Min: -3.54   Max: 19
Current: 2.1

-3.54
19
ROC (Joel Greenblatt) (%) 17.98
PMC's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.04 vs. PMC: 17.98 )
PMC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10.31   Max: 21.88
Current: 17.98

-10.31
21.88
Revenue Growth (%) -1.60
PMC's Revenue Growth (%) is ranked higher than
56% of the 435 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. PMC: -1.60 )
PMC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 11.7
Current: -1.6

0
11.7
EBITDA Growth (%) 12.60
PMC's EBITDA Growth (%) is ranked higher than
86% of the 395 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. PMC: 12.60 )
PMC' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 17.3
Current: 12.6

0
17.3
EPS Growth (%) -0.50
PMC's EPS Growth (%) is ranked higher than
70% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.50 vs. PMC: -0.50 )
PMC' s 10-Year EPS Growth (%) Range
Min: 0   Max: 66.9
Current: -0.5

0
66.9
» PMC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PMC Guru Trades in Q3 2013

Joel Greenblatt 215,492 sh (+20.4%)
HOTCHKIS & WILEY 1,282,495 sh (+6.91%)
Steven Romick -320,700 sh (unchged)
David Dreman Sold Out
Paul Tudor Jones 40,200 sh (-1.71%)
Chuck Royce 42,500 sh (-70.18%)
Jim Simons 46,300 sh (-76.21%)
» More
Q4 2013

PMC Guru Trades in Q4 2013

Joel Greenblatt 454,285 sh (+110.81%)
Jim Simons 62,000 sh (+33.91%)
Steven Romick -320,700 sh (unchged)
Chuck Royce 42,500 sh (unchged)
HOTCHKIS & WILEY Sold Out
Paul Tudor Jones 23,213 sh (-42.26%)
» More
Q1 2014

PMC Guru Trades in Q1 2014

Jim Simons 263,615 sh (+325.19%)
Joel Greenblatt 662,882 sh (+45.92%)
Chuck Royce 42,500 sh (unchged)
Steven Romick -320,700 sh (unchged)
Paul Tudor Jones 20,699 sh (-10.83%)
» More
Q2 2014

PMC Guru Trades in Q2 2014

Steven Romick -320,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PMC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Add 45.92%0.09%$20.24 - $27.71 $ 27.0111%662882
Joel Greenblatt 2013-12-31 Add 110.81%0.12%$13.46 - $22.58 $ 27.0148%454285
David Dreman 2013-09-30 Sold Out 0.12%$11.86 - $15.4 $ 27.01100%0
Joel Greenblatt 2013-09-30 Add 20.4%0.02%$11.86 - $15.4 $ 27.01100%215492
David Dreman 2013-03-31 New Buy0.14%$13.81 - $15.26 $ 27.0185%389972
Joel Greenblatt 2013-03-31 Add 44.74%0.03%$13.81 - $15.26 $ 27.0185%159710
Joel Greenblatt 2012-09-30 New Buy0.09%$9.97 - $13.3 $ 27.01127%104549
Jean-Marie Eveillard 2012-03-31 Sold Out 0.03%$12.06 - $15.39 $ 27.01121%0
Jean-Marie Eveillard 2011-12-31 Reduce -31.17%0.02%$11.91 - $16.4 $ 27.0180%513371
Jean-Marie Eveillard 2011-09-30 New Buy0.05%$10.69 - $14.73 $ 27.01101%745898
John Keeley 2011-09-30 Sold Out 0.0046%$10.69 - $14.73 $ 27.01101%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 62.20
PMC's P/E(ttm) is ranked higher than
58% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.50 vs. PMC: 62.20 )
PMC' s 10-Year P/E(ttm) Range
Min: 6.37   Max: 113.63
Current: 62.2

6.37
113.63
P/B 1.70
PMC's P/B is ranked higher than
71% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.08 vs. PMC: 1.70 )
PMC' s 10-Year P/B Range
Min: 0.57   Max: 2.38
Current: 1.7

0.57
2.38
P/S 0.50
PMC's P/S is ranked higher than
70% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.47 vs. PMC: 0.50 )
PMC' s 10-Year P/S Range
Min: 0.12   Max: 0.51
Current: 0.5

0.12
0.51
PFCF 9.30
PMC's PFCF is ranked higher than
92% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 54.55 vs. PMC: 9.30 )
PMC' s 10-Year PFCF Range
Min: 3.24   Max: 42.17
Current: 9.3

3.24
42.17
EV-to-EBIT 22.14
PMC's EV-to-EBIT is ranked higher than
62% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.38 vs. PMC: 22.14 )
PMC' s 10-Year EV-to-EBIT Range
Min: 7   Max: 34.4
Current: 22.14

7
34.4
PEG 56.80
PMC's PEG is ranked higher than
69% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. PMC: 56.80 )
PMC' s 10-Year PEG Range
Min: 0.72   Max: 57.8
Current: 56.8

0.72
57.8
Shiller P/E 34.40
PMC's Shiller P/E is ranked higher than
82% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 56.23 vs. PMC: 34.40 )
PMC' s 10-Year Shiller P/E Range
Min: 16.41   Max: 38.13
Current: 34.4

16.41
38.13
Current Ratio 3.42
PMC's Current Ratio is ranked higher than
97% of the 499 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. PMC: 3.42 )
PMC' s 10-Year Current Ratio Range
Min: 2.72   Max: 5.08
Current: 3.42

2.72
5.08
Quick Ratio 2.47
PMC's Quick Ratio is ranked higher than
96% of the 499 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.69 vs. PMC: 2.47 )
PMC' s 10-Year Quick Ratio Range
Min: 1.99   Max: 4.18
Current: 2.47

1.99
4.18

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.60
PMC's Price/Tangible Book is ranked higher than
55% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.45 vs. PMC: 14.60 )
PMC' s 10-Year Price/Tangible Book Range
Min: 1.83   Max: 15.12
Current: 14.6

1.83
15.12
Price/DCF (Projected) 0.80
PMC's Price/DCF (Projected) is ranked higher than
96% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.25 vs. PMC: 0.80 )
PMC' s 10-Year Price/DCF (Projected) Range
Min: 0.38   Max: 0.85
Current: 0.8

0.38
0.85
Price/Median PS Value 1.80
PMC's Price/Median PS Value is ranked higher than
52% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. PMC: 1.80 )
PMC' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 1.91
Current: 1.8

0.64
1.91
Price/Graham Number 6.30
PMC's Price/Graham Number is ranked higher than
59% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.14 vs. PMC: 6.30 )
PMC' s 10-Year Price/Graham Number Range
Min: 0.96   Max: 6.54
Current: 6.3

0.96
6.54
Earnings Yield (Greenblatt) 4.30
PMC's Earnings Yield (Greenblatt) is ranked higher than
57% of the 481 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.80 vs. PMC: 4.30 )
PMC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 14.3
Current: 4.3

2.9
14.3
Forward Rate of Return (Yacktman) 9.72
PMC's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 345 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.71 vs. PMC: 9.72 )
PMC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.2   Max: 33.7
Current: 9.72

8.2
33.7

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, CCKRY » details
PharMerica Corporation, a Delaware Corporation was formed on October 23, 2006. It is an institutional pharmacy services company that services healthcare facilities and provides management pharmacy services to hospitals. The Company operates institutional pharmacies and 12 specialty infusion pharmacies in 45 states. It also provides pharmacy management services to 89 hospitals in the United States. Its customers comprise of institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care settings. The Company's main business is to provide pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals, and other long-term alternative care settings. It purchases, repackages and dispenses prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers such medication to healthcare facilities for administration to individual patients and residents. The Company provides 24-hour, seven-day per week on-call pharmacist services for emergency dispensing, delivery, and/or consultation with the facility's staff or the resident's attending physician.
» More Articles for PMC

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PMC, ZBB Jun 25 2012 
Weekly CEO Buys Highlight: UTHR, PMC, ABR, AIR, SCHS Jun 23 2012 
9.51 Jun 20 2012 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP Jun 16 2012 
Weekly CEO Buys Highlight: AHT, SPN, WINA, PMC, ULBI Mar 04 2012 
PharMerica Corp. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, CONTINENTAL RESRCES, ARGO GROUP INTERNATIONAL HOLDINGS Aug 21 2010 
Weekly CEO Buys Highlight: Boston Private Financial, Argo Group, Fifth Street Finance, PharMerica Co Aug 14 2010 
PharMerica Corp. (PMC) CEO Gregory S Weishar buys 81,000 Shares Aug 13 2010 

More From Other Websites
Seattle Grandmother Makes History With Legal Marijuana Jul 24 2014
Onco360® Named to Zydelig® (Idelalisib) Limited Distribution Network; Zydelig is Available... Jul 24 2014
PharMerica Corporation Announces Second Quarter 2014 Earnings Call and Webcast Jul 14 2014
PharMerica Corporation Announces Second Quarter 2014 Earnings Call and Webcast Jul 14 2014
True-blue ‘American’ stocks beat the S&P 500 Jul 03 2014
Amerita, a Subsidiary of PharMerica, Expands into Arizona Through the Acquisition of Altius... Jul 01 2014
PHARMERICA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 19 2014
PHARMERICA CORP Files SEC form 8-K, Change in Directors or Principal Officers Jun 03 2014
PHARMERICA CORP Financials May 09 2014
PharMerica to Present at the Bank of America Merrill Lynch 2014 Health Care Conference May 09 2014
PharMerica's CEO Discusses Q1 2014 Results - Earnings Call Transcript May 02 2014
PharMerica Corporation Earnings Call scheduled for 10:00 am ET today May 01 2014
PHARMERICA CORP Files SEC form 8-K, Results of Operations and Financial Condition May 01 2014
PharMerica Reports First Quarter 2014 Results May 01 2014
Q1 2014 PharMerica Corporation Earnings Release - Before Market Open May 01 2014
PharMerica Corporation Announces First Quarter 2014 Earnings Call and Webcast Apr 18 2014
Why PharMerica (PMC) is Poised to Beat Earnings Estimates (Again) Mar 31 2014
Can PharMerica (PMC) Keep the Earnings Streak Alive This Quarter? Mar 26 2014
PharMerica Announces Date of 2014 Annual Meeting of Shareholders Mar 19 2014
PharMerica Announces Date of 2014 Annual Meeting of Shareholders Mar 19 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide